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Abstract
Background: Endoscopic treatment of post-cholecystectomy biliary strictures (PCBS) with multiple plastic biliary
stents placed sequentially is a minimally invasive alternative to surgery but requires multiple interventions.
Temporary placement of a single fully-covered self-expanding metal stent (FCSEMS) may offer safe and effective
treatment with fewer re-interventions. Long-term effectiveness of treatment with FCSEMS to obtain PCBS resolution
has not yet been studied.
Methods: In this prospective multi-national study in patients with symptomatic benign biliary strictures (N = 187)
due to various etiologies received a FCSEMS with scheduled removal at 6–12 months and were followed for 5 years.
We report here long-term outcomes of the subgroup of patients with PCBS (N = 18). Kaplan Meier analyses assessed
long-term freedom from re-stenting. Adverse events were documented.
Results: Endoscopic removal of the FCSEMS was achieved in 83.3% (15/18) of patients after median indwell of 10.9
(range 0.9–13.8) months. In the remaining 3 patients (16.7%), the FCSEMS spontaneously migrated and passed
without complications. At the end of FCSEMS indwell, 72% (13/18) of patients had stricture resolution. At 5 years
after FCSEMS removal, 84.6% (95% CI 65.0–100.0%) of patients who had stricture resolution at FCSEMS removal
remained stent-free. In addition, at 75 months after FCSEMS placement, the probability of remaining stent-free was
61.1% (95% CI 38.6–83.6%) for all patients. Stent or removal related serious adverse events occurred in 38.9% (7/18)
all resolved without sequalae.
Conclusions: In patients with symptomatic PCBS, temporary placement of a single FCSEMS intended for 10–12
months indwell is associated with long-term stricture resolution up to 5 years. Temporary placement of a single
FCSEMS may be considered for patients with PCBS not involving the main hepatic confluence.
Trial registration numbers: NCT01014390; CTRI/2012/12/003166; Registered 17 November 2009.
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Background
Endoscopic stenting is a recognized [1, 2] and increas-
ingly adopted treatment modality for benign biliary stric-
tures (BBS). Endotherapy of BBS may include any
combination of ductal dilation with biliary balloons and
extended duration endoscopic stenting. The latter in-
volves placement of multiple plastic stents (MPS) and
subsequent MPS exchanges every 3 to 4 months for ap-
proximately 1 year, or temporary placement of a fully
covered self-expanding metal stent (FCSEMS). These
endoscopic treatment modalities are all focused on re-
establishing luminal patency.
Post-operative BBS most typically result from bile duct
injury during cholecystectomy, with post-cholecystectomy
biliary strictures (PCBS) occurring in 0–0.6% of laparo-
scopic cholecystectomy cases [3–5]. PCBSs may cause
chronic cholestasis and jaundice, recurrent cholangitis,
and secondary biliary cirrhosis, all of which can lead to
serious and even fatal outcomes.
Endotherapy of post-operative BBS using a MPS tech-
nique was first reported in the late 1980s and 1990s
using one or two biliary plastic stents [6–8]. The con-
cept of using the MPS approach in a more aggressive
manner until complete disappearance of the stricture
was first reported in 2001 in a large series of 45 patients
with BBS, of which 38 were PCBS [9]. Outcomes of
endotherapy for these patients after mean follow-up of
13.7 years (range 11.7–19.8 years) was subsequently pub-
lished in 2011 [10]. Results from endotherapy using
MPS in PCBS were also reported from other studies
[11–13]. The MPS therapeutic approach has high suc-
cess rates, but requires multiple interventions and is
technically demanding. Stricture dilation is step-wise in
the MPS treatment approach. Increased number and/or
diameter of plastic stents are inserted for about 3
months, then exchanged up to a cumulative stenting
duration of approximately 1 year.
FCSEMSs, which are mounted on a delivery system
with a diameter comparable to the diameter of one plas-
tic stent, expand to a diameter similar to that of the lar-
gest bundle of MPS (seven 10 Fr plastic stents) after
approximately 1 year of multi-procedure treatments
(Fig. 1). However, use of FCSEMS for endoscopic treat-
ment of PCBS to date is considered investigational [1, 2].
This approach is gaining acceptance, but long-term
follow-up is lacking. We previously reported the results
of a prospective, non-randomized study assessing the
placement of a biliary FCSEMS (WallFlex Biliary RX
Stent; Boston Scientific, Natick, MA) with intended in-
dwell for 6–12months, in 187 patients with BBS second-
ary to chronic pancreatitis, or anastomotic BBS after
orthotopic liver transplantation, or caused by bile duct
injury during cholecystectomy (PCBS). Endoscopic re-
moval of the FCSEMS was achieved in 83.3% (15/18) of
patients with PCBS, after median indwell of 10.9 months
(range 0.9–13.8 months); of these, a stent-in-stent re-
moval technique was required in 1 patient without com-
plications. In the remaining 3 patients (16.7%) with
PCBS, the FCSEMS spontaneously migrated and passed
without complications. Stricture resolution at the end of
FCSEMS indwell was achieved in 72% (13/18) of pa-
tients. The present report provides long-term efficacy up




The design of this study (NCT01014390 and CTRI/
2012/12/003166) has been described previously [14].
The trial was approved by the Ethics Committee at each
participating center and all patients provided written in-
formed consent.
Adverse events were reported by the investigators and
categorized as related or unrelated to the study stent,
the stenting procedure, or the study stent removal pro-
cedure. An independent medical reviewer (DCL) adjudi-
cated the reported relatedness for all deaths and serious
adverse events (SAEs). This independent review was car-
ried out blinded to the study site.
Patients
Eligibility for the index FCSEMS placement procedure
included patients ≥18 years old who underwent chole-
cystectomy and who were indicated to have endo-
scopic retrograde cholangiopancreatography (ERCP)
and stent placement for treatment of BBS. Indications
for ERCP were one or more of a symptomatic bile
duct stricture, obstructive jaundice, persistent chole-
stasis and acute cholangitis. The FCSEMS was placed
either in exchange of previously placed plastic stent(s),
Fig. 1 A 10mm diameter Fully Covered Self-Expandable Metal Stent
corresponds to seven 10 Fr plastic stents
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or as initial treatment of a de novo biliary stricture as
confirmed by ERCP.
Principal exclusion criteria were history of hepatec-
tomy or liver transplantation, strictures within 2 cm of
the hilum, prior biliary SEMS, bile duct perforation or
fistula, suspected bile duct ischemia, symptomatic duo-
denal stenosis, biliary stricture of malignant etiology or
benign etiology other than cholecystectomy-related bile
duct injury, and strictures too tight to be dilated suffi-
ciently to pass the stent delivery system.
Stenting and stent removal
The Fully-Covered WallFlex Biliary RX Stent is cleared
in most countries outside of the United States for palli-
ation of biliary obstructive symptoms caused by malig-
nant biliary strictures and for treatment of BBS. In the
United States it is cleared for palliation of malignant bil-
iary strictures, but the BBS treatment clearance is re-
stricted to BBS secondary to chronic pancreatitis.
The stent is available in 5 sizes, 8 × 60mm, 8 × 80mm,
10 × 40mm, 10 × 60mm, and 10 × 80 mm. It is made of
radiopaque Nitinol wire and a silicone covering. Both
ends are flared. The delivery system is 8.5F. It is custom-
ary to deploy the stent over an 0.035 in. wire under
fluoroscopic guidance (Fig. 2).
The planned FCSEMS indwell duration was 10–12
months, which is a stenting duration similar to what is
typical in the MPS treatment. The distal (duodenal) end
of the stent has a retrieval loop to facilitate stent re-
moval. Most often, the stent is removed with rat tooth
forceps grasping the retrieval loop or by placing a snare
over the distal end of the stent.
Assessments
The goal of PCBS treatment by temporary placement of
a FCSEMS is for patients to remain stent-free for an ex-
tended period of time without interventions. The frac-
tion of stent-free patients 5 years after FCSEMS indwell
and reintervention rates were analyzed.
As previously reported [14] other key assessments
were stricture resolution at the end of FCSEMS indwell,
stricture recurrence, and adverse events. Stricture reso-
lution was defined as the absence of a biliary stricture
requiring restenting at the end of FCSEMS indwell.
Stricture recurrence was defined as the need for restent-
ing after stricture resolution, namely recurrence of a pre-
viously resolved stricture. Patients were followed until
they underwent restenting or until they were stent-free
for 5 years, whichever came first. For patients who failed
the stent-free status earlier than 5 years after the end of
FCSEMS indwell, further treatments were documented
in an ad-hoc fashion.
Biliary obstructive symptoms, adverse events, and rein-
terventions were assessed at 1 week; at 1, 3, 6, and 9
Fig. 2 a Cholangiogram showing a post cholecystectomy stricture at > 2 cm from the main hepatic confluence near the laparoscopic clips
(arrow). b Fully Covered Wallflex stent is deployed. c Stricture resolution (arrow) after Wallflex removal
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months after FCSEMS placement; at FCSEMS removal;
and at 1, 3, 6, 12, 18, 24, 36, 48, and 60 months after
FCSEMS removal. Proximal (towards the hilum) or par-
tial distal (in the direction of the duodenum) migration
of FCSEMS was assessed by ERCP.
ERCP was performed before and after FCSEMS place-
ment, at FCSEMS removal, and at the time of reported
recurrence of biliary obstructive symptoms.
Statistical methods
Summary statistics were performed to analyze the data for
the study, specifically for continuous measurements, mean
and standard deviation or median and range was reported
and a Wilcoxon rank sum test was used to test between
groups where appropriate. For binary data, the rate was re-
ported and a 95% exact confidence interval (CI) was calcu-
lated where applicable. Stricture recurrence and freedom
from restenting was analyzed using Kaplan-Meier tech-
niques. Univariate and multivariate analyses were used for
determining predictors of various endpoints. Specifically, lo-
gistic regression using a Firth bias adjustment was used for
stricture resolution. For complications and stricture recur-
rence, a Cox proportional hazards model was performed.
Both were performed using the model building technique of
step-wise regression, with a p-value ≤0.10 to stay in the
model and > 0.10 to exit the model. The significance level
for all analyses was set at 0.05. All analyses were performed
using SAS version 9.4.
Results
Patients
Eighteen patients were enrolled between December 2009
and May 2011 at 9 centers in Europe (6), India, Chile,
and Canada. Mean age was 53.9 ±13.1 years and 33.3%
(6/18) were male. The PCBS was located in the distal
(4), mid (6) or proximal (8) bile duct. Most patients
(77.8%, 14/18) had prior treatment of the PCBS with one
or more plastic stents. All 18 patients completed the
study (Table 1).
Stent placement
The majority of patients (89%, 16/18) received FCSEMS
that were 10mm in diameter. All FCSEMS were placed
in trans-papillary position. Stent length was 40mm (3),
60 mm (10), or 80 mm (5). One stent each were 8 mm ×
60mm and 8mm × 80mm in size.
Shorter-term results
Stent removal or migration
Endoscopic FCSEMS removal occurred in 83.3% (15/
18) of patients after median indwell of 10.9 months
(range 0.9–13.8 months; Table 2). Endoscopic removal
was performed at the planned removal time in 11 pa-
tients, with median indwell duration of 11.5 months
(range 10.4–13.8 months). Early uneventful endoscopic
FCSEMS removal was prompted by cholangitis in 4 pa-
tients after median indwell duration of 3.8 months
(range 0.9–8.9 months).
In the remaining 3 patients (16.7%) with PCBS, the
FCSEMS spontaneously migrated and passed without
complications. One of these complete distal migrations
(CDMs) was noted at the time of intended removal,
10.8months. The other two were found at 5.1 and 6.3
months, one suffered from cholangitis and the other had a
recurrent stricture. However, in each of these 3 patients
the true indwell duration of the FCSEMS is not known.
Stricture resolution
At the end of FCSEMS indwell, 72% (13/18) of patients
had stricture resolution. Of these, 10 patients had
FCSEMS indwell duration as planned, 2 underwent early
FCSEMS removal due to cholangitis after 59 and 174
days, and 1 had asymptomatic CDM. These 13 patients
were considered at risk for stricture recurrence during
subsequent follow-up. (Fig. 3).
Excluding the 3 patients with CDM after unknown in-
dwell duration, median FCSEMS indwell duration was 11.3
(range 1.9–13.8) months for the 12 patients with stricture
resolution at endoscopic FCSEMS removal vs. 8.9 (range
Table 1 Baseline characteristics of patients with post-
cholecystectomy biliary strictures
Summary Statistics
Age 53.9 ±13.1 (18)
Male 33.3% (6/18)
Total Bilirubin Level (mg/dL) 1.6 ±2.0 (17)




Proximal (within 2 cm of the hilum) 44.4% (8/18)
Sphincterotomized 100.0% (18/18)
Any Prior Plastic Stenting History 77.8% (14/18)




Study Stent Size (mm)
8 × 60 5.6% (1/18)
8 × 80 5.6% (1/18)
10 × 40 16.7% (3/18)
10 × 60 50.0% (9/18)
10 × 80 22.2% (4/18)
Mean Procedure Time (mins) 25.0±16.6 (18)
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0.9–10.8) months for the 3 patients without stricture reso-
lution at endoscopic FCSEMS removal (P = 0.12). Stricture
resolution occurred in 90.9% (10/11) of patients after in-
dwell duration as planned vs. 50% (2/4) after early FCSEMS
removal due to cholangitis (P = 0.15).
In a univariate analysis of predictors (including age,
sex, proximal stricture location, prior plastic stenting,
procedure time, and stent length) for stricture resolution




At 60months of follow-up, of the 13 patients with stricture
resolution at FCSEMS removal or CDM, 2 experienced stric-
ture recurrence, one associated with cholangitis after 2.6
months and one with biliary obstruction after 13.1months.
In a univariate analysis of predictors (including age,
sex, proximal stricture location, prior plastic stenting,
procedure time, and stent length) for stricture recur-
rence at FCSEMS removal, no significant predictors
were found (Fig. 5).
Freedom from Restenting
In Kaplan-Meier analysis, at 5 years after FCSEMS re-
moval, the probability of remaining stent-free was 84.6%
(95% CI 65.0–100.0%) for patients who had stricture
resolution at FCSEMS removal (Fig. 6).
In Kaplan-Meier analysis, at 75 months after FCSEMS
placement, the probability of remaining stent-free was
61.1% (95% CI 38.6–83.6%) for all patients who had
FCSEMS placement for treatment of PCBS (Fig. 7).
Treatment after stent dysfunction
Throughout the entire course of the study, 7 patients
were restented due to loss of stent functionality or re-
currence of stricture. Two developed cholangitis leading
to early stent removal; 2 had symptoms of biliary ob-
struction associated with CDM; 1 had unresolved stric-
ture at the time of planned FCSEMS removal; and 2 had
recurrence of the stricture after a stent-free period.
All 7 of these patients were restented with plastic bil-
iary stents. Subsequent to plastic restenting, 5 patients
underwent 1–3 additional plastic stenting procedures
and ultimately were stent-free with normal liver function
tests at 5–7 years follow-up after restenting; 1 patient





Endoscopic FCSEMS Removal 83.3% (15/18) 58.6–96.4%
Planned, at 10–12 months 61.1% (11/18) 35.8–82.7%
Early, prior to 10–12 months 22.2% (4/18) 6.4–47.6%
Spontaneous CDM 16.7% (3/18) 3.9–41.4%
Stricture Resolution at End of FCSEMS Indwell 72.2% (13/18) 46.5–90.3%
Overall Adverse Event Rate 38.9% (7/18) 17.3–64.3%
Abbreviations: CDM complete distal migration, CI confidence interval, FCSEMS fully-covered, self-expanding metal stent, PCBS post-cholecystectomy biliary stricture
Fig. 3 Patient flowchart. The flowchart shows occurrence of post-cholecystectomy biliary strictures resolution after FCSEMS removal and the
stricture recurrence at 5 years follow-up in the 13 cases with initial stricture resolution
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underwent a surgical biliary-enteric anastomosis; and 1
patient was lost to follow-up.
Adverse events
Stent-related or procedure-related SAEs occurred in
38.9% (7/18) (95% CI 17.3–64.3%) of patients, including
cholangitis (6) and pancreatitis (1), and are detailed as
follows. Four patients experienced cholangitis that led to
early removal of the FCSEMS, 2 of which were immedi-
ately restented with plastic stents and 2 remained stent-
free for 5 years. One patient developed cholangitis associ-
ated with spontaneous CDM of the FCSEMS and was
restented with plastic stents. One patient presented with
cholangitis at 9.7 months after FCSEMS placement
followed by FCSEMS removal as planned after 10.8
months of indwell, without stricture resolution; the patient
Fig. 4 Independent variables by post-cholecystectomy biliary strictures resolution at FCSEMS removal. Univariate Forest Plot of Stricture
Resolution at Removal
Fig. 5 Independent variables by post-cholecstectomy biliary strictures recurrence after initial resolution at FCSEMS removal. Univariate Forest Plot
of Stricture Recurrence after Resolution
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was restented with plastic stents One patient experienced
mild post ERCP pancreatitis after FCSEMS removal as
planned, which resolved 6 days post-FCSEMS removal
without residual effects; the patient remained stent-free
for 2.9 months. All SAEs resolved without sequalae.
Discussion
In this small, prospective, nonrandomized study, 13 of
18 patients with PCBS experienced stricture resolution
upon FCSEMS removal or CDM, and at 5 years follow-
up, 84.6% (95% CI 65.0–100.0%) of these patients with
Fig. 6 Kaplan-Meier analysis of freedom from post-cholecystectomy biliary strictures recurrence in patients who had stricture resolution at
FCSEMS removal. At 60 months after FCSEMS removal, 84.6% (95% CI 65.0–100%) of patients who had stricture resolution at FCSEMS removal
remained stent-free
Fig. 7 Kaplan-Meier analysis of freedom from restenting in all patients treated for post-cholecystectomy biliary strictures. At 75 months after
FCSEMS placement, 61.1% (95% CI 38.6–83.6%) of patients who had FCSEMS placement for treatment of PCBS remained stent-free
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initial resolution remained stent-free. In Kaplan-Meier
analysis, at 75 months after FCSEMS placement, the
probability of remaining stent-free was 61.1% (95% CI
38.6–83.6%) for all patients who received an FCSEMS
for treatment of PCBS. The overall adverse event rate
was 38.9% (95% CI 17.3–64.3%). These results suggest
safe and effective treatment of symptomatic PCBS not
involving the main hepatic confluence.
Endoscopic removal took place as planned after 10–12
month indwell in 11 patients, early due to cholangitis in 4
patients, and 3 had CDM. Although there was no signifi-
cant difference in stricture resolution between the groups
(90.9% with indwell duration as planned vs. 50% after early
removal, P = 0.15), the small sample size may have limited
the ability to detect a difference in whether the duration
of stenting affects stricture resolution (Table 3).
In 1 patient, the FCSEMS was difficult to remove due
to the proximal end being embedded in hyperplastic tis-
sue at the level of cholecystectomy clips; the attempted
stent removal was stopped and a new FCSEMS was
placed inside of the study stent. Both FCSEMSs were re-
moved endoscopically and uneventfully 2 weeks later ac-
cording to the “stent-in-stent technique” [15]. This
patient remained stent-free for 2.5 months, and then had
early stricture recurrence maybe related to the develop-
ment of hyperplasia and subsequent trauma due to diffi-
cult FCSEMS retrieval. The rate of cholangitis in our
series was high (6/18) but were successfully resolved by
medical/endoscopic treatment without any impact on
stricture resolution.
Larger series described the use of FCSEMS to dilate
BBS, but looking into subgroup analysis these studies
included fewer cases of PCBS, compared to our ex-
perience [16–19]. Our study also provided longer
follow-up than most other published reports. None-
theless, relatively promising results were demonstrated
pertaining to stricture patency [20, 21]. In addition to
maintaining bile duct patency and preventing stricture
recurrence, endoscopic therapy of BBS reduced mor-
bidity and mortality, as compared with surgical ther-
apy [22]. Typical endotherapy with MPS includes stent
exchanges every 3–4 months, resulting in at least 3
procedures per year. In the present study, 11 patients
had their FCSEMS removed at the planned timeframe
of 10–12 months. When compared with multiple ex-
changes of plastic stents over the course of 1 year, this
indicates that these 11 patients had approximately 2
fewer endoscopic procedures than they would have if
treated with plastic stents. FCSEMS can bring the ad-
vantage of fewer ERCPs leading to better patient
compliance with reduced burdensome endoscopic
treatments. Moreover, maximal dilation is reached
rapidly after FCSEMS placement compared to a pro-
gressive step-wise dilation when inserting MPS in in-
creasing numbers in successive plastic stenting
episodes. The potential associated post- FCSEMS
placement pain was not observed in the present study.
It should also be noted that reaching the same max-
imal dilation with MPS compared to an 8 mm or 10
mm diameter FCSEMS is not always technically feas-
ible. Accordingly, given the high rate of continued
stricture resolution and freedom from restenting in
the present study at 36, 48, and even 60 months
(Fig. 6), treatment with FCSEMS should be considered
a viable long-term therapy for patients with PCBS not
involving the main hepatic confluence.
Three patients in the present study experienced CDM.
Spontaneous migration may be a possible risk factor for
failure of stricture resolution. Of these 3 patients, only 1
had stricture resolution [1, 2]. Antimigration mechanism
for FCSEMS to avoid migration seem promising but
need further evaluation [1, 2].
Seven patients were restented with plastic biliary stents
and 5 underwent repeated ERCPs for stent exchanges.
The possibility for endoscopic retreatment of PCBS re-
currence represents the key advantage of endotherapy
which can be repeated using the same access. One pa-
tient underwent a surgical biliary-enteric anastomosis
meaning that endoscopy does not preclude future surgi-
cal options if needed.
The limitations of our study include a small sample
size and the lack of a control group. Larger patient sam-
ples specific to PCBS with follow-up durations compar-
able to that evaluated in our study are expected.
Additionally, it should be noted that treatment with
FCSEMS is not a panacea for all PCBS and is limited to
strictures located > 2 cm from the main hepatic conflu-
ence, due to the risk of side-branch occlusion [1, 2].
Table 3 Results of endoscopic dilation of post-cholecystectomy biliary strictures with fully-covered self-expanding metal stent
(FCSEMS) by removal type
Planned Removal Early Removal CDM
Number of patients (n) 11 4 3
Median months of indwell time (range) 11.5 (10.4–13.8) 3.8 (0.9–8.9) 6.2 (5.1–10.8)
Stricture Resolution at End of FCSEMS Indwell (n) 10 2 1
Stent free status at 5 years (n) 8 2 1
Abbreviations: CDM complete distal migration, CI confidence interval, FCSEMS fully-covered, self-expanding metal stent
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Conclusion
In conclusion, this prospective multi-center study indi-
cates that treatment with FCSEMS is effective for main-
taining long-term stricture resolution in patients with
“non-hilar” PCBS. Randomized controlled trials are
needed to better assess the role and the long-term effi-
cacy of FCSEMS compared with MPS in the treatment
of PCBS.
Abbreviations
BBS: Benign biliary strictures; CDMs: Complete distal migrations;
CI: Confidence interval; ERCP: Endoscopic retrograde
cholangiopancreatography; FCSEMS: Fully-covered self-expanding metal
stent; MPS: Multiple plastic stents; PCBS: Post-cholecystectomy biliary
strictures; SAEs: Serious adverse events
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